Partner With Us

Illuminating biologics discovery with AI

Scroll + Explore

AI and humans excel at different tasks. We are pushing the limit of artificial intelligence in extracting hidden principles from large complex dataset, while leveraging our human creativity and expertise to make informed decisions. greater R&D success on the path toward the clinic.

Scroll + Explore

Technology

World-leading biologics AI models powered by a massive, proprietary biologics dataset

Purpose-Built, Fully Validated
  • 01 AI ENGINES
  • 02 WET LAB
  • 03 DATABASE
  • Model

    protein complex structures to inform candidate selection and engineering.

  • Model

    protein complex structures to inform candidate selection and engineering.

  • Model

    protein complex structures to inform candidate selection and engineering.

A state-of-the-art wet lab underpins our advanced AI models and one-stop solutions for partners.

Proprietary biologics database tailor-made for AI

AtlaX

Public dataset

Data size

Granularity

Trend line

Seq

Binder

Develop-ability

KD

Epitope

Bubble size proportional to cost of data

Label-Free
Qualitative
Quantitative
HARD

TARGETS
NEXT-GEN

ENGINEERING
NEXT-GEN

ENGINEERING
ADVANCED

MODALITIES
news & events

Explore our upcoming news & events

Together, let’s push the boundaries of medicine

The future of biotechnology is collaborative. We believe the best solutions come from working together with companies and researchers who share our vision. Are you ready to push the boundaries of what’s possible?

Partner with us
Case Study

Tapping into a greater search space for more quality hits using AI.

Immune Repertoire Analysis

In silico screening of millions of antibody sequences in the immune repertoire 

K+
VL Clonotypes
K+
VH Clonotypes
Animals
NCS Datasets
M+
Unique VL Sequences
M+
Unique VH Sequences
Results and Insights

XploreSeqTM Identifies Hits with High Accuracy

XploreSeqTM routinely sequences millions of BCRs and identifies hits with high confidence (see figure). In this project, XploreSeq predicted 717 binders, from which 48 were randomly chosen for expression and testing. 66.7% (32/48) were confirmed to be binders, and only 18.6% (6/32) binders overlap with hybridoma hits.

Read more case studies
Privacy Settings
We use cookies to enhance your experience while using our website. If you are using our Services via a browser you can restrict, block or remove cookies through your web browser settings. We also use content and scripts from third parties that may use tracking technologies. You can selectively provide your consent below to allow such third party embeds. For complete information about the cookies we use, data we collect and how we process them, please check our Privacy Policy
Youtube
Consent to display content from - Youtube
Vimeo
Consent to display content from - Vimeo
Google Maps
Consent to display content from - Google
Spotify
Consent to display content from - Spotify
Sound Cloud
Consent to display content from - Sound
Save
Partner With Us